Insider Selling: Progyny (NASDAQ:PGNY) CFO Sells 21,303 Shares of Stock

Progyny, Inc. (NASDAQ:PGNY) CFO Mark Livingston sold 21,303 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $25.50, for a total transaction of $543,226.50. Following the transaction, the chief financial officer directly owned 48,358 shares of the company’s stock, valued at $1,233,129. The trade was a 30.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Progyny Stock Performance

Shares of NASDAQ:PGNY traded down $0.45 during trading hours on Wednesday, hitting $25.40. The stock had a trading volume of 1,526,154 shares, compared to its average volume of 1,440,221. The stock’s fifty day simple moving average is $21.13 and its 200 day simple moving average is $21.94. The firm has a market capitalization of $2.19 billion, a price-to-earnings ratio of 40.32, a PEG ratio of 2.11 and a beta of 1.29. Progyny, Inc. has a 1-year low of $13.50 and a 1-year high of $27.25.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.06. Progyny had a return on equity of 10.71% and a net margin of 4.46%.The business had revenue of $313.35 million during the quarter, compared to analyst estimates of $299.23 million. During the same period in the prior year, the company posted $0.11 EPS. The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS. Q4 2025 guidance at 0.370-0.400 EPS. As a group, research analysts anticipate that Progyny, Inc. will post 0.6 EPS for the current year.

Institutional Trading of Progyny

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cetera Trust Company N.A grew its position in Progyny by 303.1% in the second quarter. Cetera Trust Company N.A now owns 1,310 shares of the company’s stock worth $29,000 after buying an additional 985 shares during the last quarter. Federated Hermes Inc. boosted its stake in shares of Progyny by 147.3% during the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock worth $30,000 after acquiring an additional 819 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Progyny in the 1st quarter worth $44,000. Militia Capital Partners LP raised its position in shares of Progyny by 100.0% during the first quarter. Militia Capital Partners LP now owns 2,000 shares of the company’s stock worth $45,000 after purchasing an additional 1,000 shares during the period. Finally, Versant Capital Management Inc raised its position in shares of Progyny by 61.8% during the third quarter. Versant Capital Management Inc now owns 2,340 shares of the company’s stock worth $50,000 after purchasing an additional 894 shares during the period. 94.93% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 price objective (up from $26.00) on shares of Progyny in a research note on Friday, August 8th. Raymond James Financial set a $28.00 price target on shares of Progyny in a research report on Friday, August 8th. Wall Street Zen upgraded shares of Progyny from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Canaccord Genuity Group boosted their target price on Progyny from $23.00 to $26.00 and gave the stock a “hold” rating in a report on Monday. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Progyny in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Progyny has an average rating of “Moderate Buy” and a consensus price target of $27.33.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.